FR2861993B1 - Complexe moleculaire anti restenose pour endoprothese intracoronaire - Google Patents

Complexe moleculaire anti restenose pour endoprothese intracoronaire

Info

Publication number
FR2861993B1
FR2861993B1 FR0313025A FR0313025A FR2861993B1 FR 2861993 B1 FR2861993 B1 FR 2861993B1 FR 0313025 A FR0313025 A FR 0313025A FR 0313025 A FR0313025 A FR 0313025A FR 2861993 B1 FR2861993 B1 FR 2861993B1
Authority
FR
France
Prior art keywords
drugs
molecular complex
iloprost
colchicine
restenosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0313025A
Other languages
English (en)
Other versions
FR2861993A1 (fr
Inventor
Jean Claude Rigaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0313025A priority Critical patent/FR2861993B1/fr
Publication of FR2861993A1 publication Critical patent/FR2861993A1/fr
Application granted granted Critical
Publication of FR2861993B1 publication Critical patent/FR2861993B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Complexe Moléculaire déposé sur le « Stent » destiné à diminuer le pourcentage de Resténose après angioplastie coronarienne transluminale .L'invention consiste dans l'association sur le stent de 2 couches de polyméres associées à des drogues actives sur la Resténose :La premiére couche à base de polyethyléne etheroxide de castor permet une libération instantanée de drogues ( Colchicine , Iloprost , Allopurinol , Vitamine E )ayant une action antithrombotique , anti-inflammatoire , anti radicaux libres , antiproliférative, favorisant la réendothélialisation.La deuxiéme couche à base de poly (lactide-co-glycolide) Acid dans une proportion de 50/50 permettant une libération prolongée de drogues sur une durée de 140 jours environ (Colchicine et Iloprost) agissant sur la prolifération anarchique des cellules qui se reconstruisent et sur les phénomes thrombotiques qui pourraient survenir .
FR0313025A 2003-11-06 2003-11-06 Complexe moleculaire anti restenose pour endoprothese intracoronaire Expired - Fee Related FR2861993B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0313025A FR2861993B1 (fr) 2003-11-06 2003-11-06 Complexe moleculaire anti restenose pour endoprothese intracoronaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0313025A FR2861993B1 (fr) 2003-11-06 2003-11-06 Complexe moleculaire anti restenose pour endoprothese intracoronaire

Publications (2)

Publication Number Publication Date
FR2861993A1 FR2861993A1 (fr) 2005-05-13
FR2861993B1 true FR2861993B1 (fr) 2006-01-21

Family

ID=34508286

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0313025A Expired - Fee Related FR2861993B1 (fr) 2003-11-06 2003-11-06 Complexe moleculaire anti restenose pour endoprothese intracoronaire

Country Status (1)

Country Link
FR (1) FR2861993B1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420628T1 (de) * 1993-07-19 2009-01-15 Angiotech Pharm Inc Anti-angiogene mittel und verfahren zu deren verwendung
US7208011B2 (en) * 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6544541B1 (en) * 1999-06-02 2003-04-08 Cardiovascular Solutions, Inc. Devices and compounds for treating arterial restenosis
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
CN1568166A (zh) * 2001-10-15 2005-01-19 荷姆泰克股份有限公司 预防再狭窄的涂层支架

Also Published As

Publication number Publication date
FR2861993A1 (fr) 2005-05-13

Similar Documents

Publication Publication Date Title
Abizaid et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients: insights from the RAVEL trial
Serruys et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES)
Topol et al. Frontiers in interventional cardiology
WO2007126606A3 (fr) Dégradation contrôlée et libération de médicament par des stents
WO2009079389A3 (fr) Endoprothèse à élution de médicaments
BR0110778A (pt) combinações de drogas úteis para prevenção de restenose
EP1127582A3 (fr) Utilisation d'un stent muni de cladribine pour la prévention de resténose
NZ588549A (en) Stents having bioabsorbable layers
ATE251449T1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
DE602005016044D1 (de) Deckbeschichtung enhaltend Heparin für kontrollierte Wirkstoffabgabe
Raval et al. Mechanism and in vitro release kinetic study of sirolimus from a biodegradable polymeric matrix coated cardiovascular stent
DE69926255D1 (de) Bioaktive prothesen aus leitendem material beschichtet mit einem polymer und einer substanz mit immunsuppressiven , antistenosen und antithrombosen eigenschaften
ATE369096T1 (de) Stent für die freisetzung von aktiven substanzen
WO2008118606A3 (fr) Couche barrière en métal biodégradable pour une endoprothèse à élution de médicament
EP2671540A3 (fr) Capture de cellules endothéliales progénitrices avec un dispositif médical implantable à élution de médicament
BR0213279A (pt) Revestimento de stents para impedir a restenose
Barbato et al. A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study
WO2004030678A8 (fr) Compositions polymeres contenant des agents bioactifs et procedes d'utilisation de celles-ci
WO2007047473A3 (fr) Procedes d'administration d'analogues de rapamycine avec des anti-inflammatoires au moyen de dispositifs medicaux
CY1110071T1 (el) Πολυμερες επιχρισμα για ιατρικα μηχανηματα
Romaguera et al. Amphilimus-vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial
WO2008063319A3 (fr) Procédés d'administration d'analogues à la rapamycine avec des anti-inflammatoires au moyen de dispositifs médicaux
Rogers Optimal stent design for drug delivery.
US9040071B2 (en) Pary-xylene based microfilm elution devices
Maillard et al. Evaluation of the safety and efficacy of the cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high‐risk patients: The E‐cobra study

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080930

RN Application for restoration
FC Favourable decision of inpi director general on an application for restauration.
ST Notification of lapse

Effective date: 20100730